雷替曲塞联合奥沙利铂经肝动脉化疗栓塞术在不可切除肝癌中的应用效果

肝脏 ›› 2026, Vol. 31 ›› Issue (7): 1000-1003.

雷替曲塞联合奥沙利铂经肝动脉化疗栓塞术在不可切除肝癌中的应用效果

孙寅, 赵家运, 胡周, 曾小川, 罗小峰

448000 荆门湖北省荆门市中心医院肝胆胰外科

收稿日期:2025-07-27 出版日期:2026-07-31 发布日期:2026-08-21
通讯作者: 罗小峰,Email:sunyin19861129@163.com
基金资助:
荆门市引导性科研计划项目(2021YDKY013)

The efficacy of raltitrexed combined with oxaliplatin in transarterial chemoembolization for unresectable hepatocellular carcinoma

Sun Yin, Zhao Jiayun, Hu Zhou, Zeng Xiaochuan, Luo Xiaofeng

Department of Hepatobiliary Pancreatic Surgery, Jingmen Central Hospital, Jingmen 448000, China

Received:2025-07-27 Online:2026-07-31 Published:2026-08-21
Contact: Luo Xiaofeng,Email:sunyin19861129@163.com

摘要/Abstract

摘要： 目的探讨雷替曲塞联合奥沙利铂经肝动脉化疗栓塞术(TACE)在不可切除肝癌中的应用效果。方法纳入2019年1月至2023年1月湖北荆门市中心医院收治的104例不可切除肝癌患者,随机分为两组,各52例,分别接受吡柔比星+奥沙利铂TACE(对照组)和雷替曲塞+奥沙利铂TACE(观察组)治疗4个疗程(3周/疗程),比较两组疗效、肿瘤标志物、肝功能、不良反应及2年随访的总生存期和生存率。结果观察组总有效率(75.0% vs. 53.9%)、肿瘤标志物水平[AFP(104.5±12.2) ng/mL、CEA (16.4±2.3) ng/mL、CA19-9 (25.2±3.5) U/mL]及肝功能改善均显著优于对照组(均P<0.05);其治疗相关不良反应发生率低于对照组(P<0.05)。随访2年显示,观察组总生存期与生存率均更高(均P<0.05)。结论雷替曲塞联合奥沙利铂TACE治疗不可切除肝癌可提升临床疗效。

关键词: 雷替曲塞, 奥沙利铂, 经肝动脉化疗栓塞术, 不可切除肝癌

Abstract: Objective To investigate the efficacy of raltitrexed combined with oxaliplatin in transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC). Methods A total of 104 patients with unresectable HCC were enrolled in Jingmen Central Hospital between January 2019 and January 2023. They were randomly divided into two groups (n=52 each) using a random number table. The control group received pirarubicin+oxaliplatin TACE, while the observation group received raltitrexed+oxaliplatin TACE. Treatment was administered every 3 weeks for a total of 4 cycles. Adverse reactions during treatment were recorded. All patients were followed up for 2 years to assess progression-free survival (PFS) and survival rates. Results The total effective rate in the observation group was significantly higher than that in the control group (P<0.05). Post-treatment tumor marker levels in the observation group were (AFP: 104.5 ± 12.2) ng/mL, (CEA: 16.4 ± 2.3) ng/mL, and (CA19-9: 25.2 ± 3.5) U/mL, all of which were significantly lower than those in the control group, while liver function indices showed greater improvement (P<0.05 for all comparisons). The incidence of treatment-related adverse reactions was lower than that in the control group. Follow-up results demonstrated that overall survival rates and overall survival were significantly higher in the observation group (P<0.05). Conclusion Raltitrexed combined with oxaliplatin TACE demonstrates superior efficacy in treating unresectable HCC, improves liver function, and does not increase the risk of adverse reactions.

Key words: Raltitrexed, Oxaliplatin, Transarterial chemoembolization, Unresectable hepatocellular carcinoma

孙寅, 赵家运, 胡周, 曾小川, 罗小峰. 雷替曲塞联合奥沙利铂经肝动脉化疗栓塞术在不可切除肝癌中的应用效果[J]. 肝脏, 2026, 31(7): 1000-1003.

Sun Yin, Zhao Jiayun, Hu Zhou, Zeng Xiaochuan, Luo Xiaofeng. The efficacy of raltitrexed combined with oxaliplatin in transarterial chemoembolization for unresectable hepatocellular carcinoma[J]. Chinese Hepatolgy, 2026, 31(7): 1000-1003.

/ 推荐

参考文献

[1] Xue J, Yang S, Zhang S S,et al. Deciphering the multifaceted immune landscape of unresectable primary liver cancer to predict immunotherapy response[J]. Adv Sci (Weinh), 2024 , 11(47):e2309631.
[2] Tian Y, Qi X, Aljbri A,et al. Case report: pancreatic neuroendocrine tumor with liver metastasis and portal vein thrombosis[J]. Front Oncol, 2022, 11:809129.
[3] Wang L, Ma J, Chen C,et al. Isoquercitrin alleviates pirarubicin-induced cardiotoxicity in vivo and in vitro by inhibiting apoptosis through Phlpp1/AKT/Bcl-2 signaling pathway[J].Front Pharmacol, 2024, 15:1315001.
[4] Singh A, Ottavi S, Krieger I,et al. Redirecting raltitrexed from cancer cell thymidylate synthase to mycobacterium tuberculosis phosphopantetheinyl transferase[J]. Sci Adv, 2024, 10(11):eadj6406.
[5] Bi Y, Wang Y, Zhang W,et al. Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma[J]. Cancer Imaging, 2023, 23(1):19.
[6] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].中华肝脏病杂志,2020,28(2):112-128.
[7] Wei J, Hu Y, Yu J,et al. Predictive value of hepatic venous pressure gradient and efficacy and significance of early PTVE for gastrointestinal bleeding after TACE for liver cancer[J]. J Cancer Res Ther, 2022, 18(7):1967-1972.
[8] Zhang L, Chen H, Song Y,et al. MiR-325 promotes oxaliplatin-induced cytotoxicity against colorectal cancer through the HSPA12B/PI3K/AKT/Bcl-2 pathway[J]. Dig Dis Sci, 2021, 66(8):2651-2660.
[9] Royer B, Schmitt A, Nguyen T,et al. Exposure-response analysis of raltitrexed assessing liver toxicity[J]. Br J Clin Pharmacol, 2021, 87(3):1327-1337.
[10] Gallois C, Hafliger E, Auclin E, et al. First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an association des gastro-entérologues oncologues (AGEO) multicentre study[J]. Dig Liver Dis, 2022, 54(5):684-691.
[11] Qi C, Gao H, Li S,et al. A case-control study on the correlation between thymidylate synthase gene polymorphisms and raltitrexed treatment combined with transcatheter arterial chemoembolization in hepatocellular carcinoma treatment[J]. Genet Test Mol Biomarkers, 2020, 24(3):156-164.
[12] Wu Y, Zheng S, Zhang Z,et al. Hepatic arterial infusion chemotherapy with oxaliplatin plus raltitrexed as an alternative option in advanced hepatocellular carcinoma patients with failure of, or unsuitability for, transarterial chemoembolization[J]. Medicina (Kaunas), 2022, 58(10):1343.
[13] Liu B, Zhu X, Gao S,et al. Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma[J]. J Interv Med, 2019, 2(2):91-96.
[14] Schaber E N, Ivanova N, Iliev S,et al. Initial stages of spontaneous binding of folate-based vectors to folate receptor-α observed by unbiased molecular dynamics[J]. J Phys Chem B, 2021 , 125(28):7598-7612.
[15] Chen S, Wang X, Yuan B, et al. Apatinib plus hepatic arterial infusion of oxaliplatin and raltitrexed for hepatocellular carcinoma with extrahepatic metastasis: phase II trial[J]. Nat Commun, 2024, 15(1):8857.
[16] Liu Z, Cai J, Jiang G,et al. Novel Platinum(IV) complexes intervene oxaliplatin resistance in colon cancer via inducing ferroptosis and apoptosis[J]. Eur J Med Chem, 2024, 263:115968.
[17] Zheng B, Chen X, Chen F,et al. 5-Iodotubercidin inhibits the growth of insulinoma cells by inducing apoptosis[J]. Neuroendocrinology, 2023, 113(6):641-656.
[18] Bi Y, Du T, Pan W,et al. Transcatheter arterial chemoembolization is safe and effective for patients with late-stage or recurrent oral carcinoma[J]. Front Oncol, 2022, 12:831583.
[19] 刘东辉,于士龙,张北光,等. 雷替曲塞联合奥沙利铂及经导管动脉化疗栓塞术TACE治疗不可切除肝癌的疗效[J]. 中国老年学杂志,2023,43(21):5167-5170.
[20] Tu X, Zhang W, Li S,et al. Efficacy of hepatic arterial infusion chemotherapy in patients with primary liver cancer with portal vein tumor thrombosis: a comparative analysis of different perfusion chemotherapeutic regimens[J]. Eur J Med Res, 2024, 29(1):465.